What is Pentadeca Arginate (PDA)?
Pentadeca Arginate (PDA) carries the same 15-amino-acid sequence as BPC-157 (GEPPPGKPADDAGLV) but as an arginate salt. Suppliers describe higher stability in solution; independent structural data are scarce.
More data in the lexicon entry on Pentadeca Arginate.
State of research
Pentadeca arginate appeared around 2023, when BPC-157 was restricted in US compounding. Chemically it is not a new peptide: the sequence GEPPPGKPADDAGLV is identical, only the counter-ion differs. Most BPC-157 products are acetate salts; PDA is the arginate salt.
Whether the salt measurably changes stability, solubility or tissue behaviour has barely been studied. Researchers working with PDA therefore rely on the BPC-157 literature: angiogenesis and tendon, muscle and gut regeneration in animal models. A clean comparison runs both salt forms side by side; for an overview see BPC-157 in research.
Status and quality
Pentadeca arginate is not approved as a medicine; its sequence is identical to BPC-157, which is on the WADA Prohibited List. Peptidkauf sells Pentadeca Arginate (PDA) solely as a research reagent for laboratory and in-vitro use and gives no dosing or application advice.
An independent laboratory tests every batch for purity (HPLC), identity and measured content before it goes on sale; the reports and their verification keys are in the lab report archive. The material ships as lyophilised powder in a glass vial; storage and laboratory handling are covered under storage & handling.
Related products and articles
The acetate original: BPC-157. Oral: BPC-157 capsules. Combination: BPC-157 + TB-500.
